Trial
NCT03051672
Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Dana-Farber Cancer Institute
Collaborators
Merck Sharp & Dohme LLC
Condition
Metastatic Breast Cancer
Intervention
Pembrolizumab
Why stopped
Based on two-stage design, the study ended at stage 1 with no evidence of promise based on pre-specified decision rule.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-04-27